Literature DB >> 2529062

Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin.

I Karádi1, L Romics, G Pálos, J Domán, I Kaszás, A Hesz, G M Kostner.   

Abstract

We measured serum cholesterol, triglyceride, and lipoprotein Lp(a) concentrations in serum of 37 patients with massive proteinuria of different origin, comparing values with those for age- and sex-matched controls and finding significantly increased Lp(a) concentration in the total group of patients compared with controls. Lp(a) concentration was not correlated with serum cholesterol, triglyceride, serum creatinine, daily urinary protein loss, or selectivity index. Selecting the patients according to their histological diagnosis obtained by renal needle biopsy, we found divergent results in seven patients with minimal change disease (MCD) compared with 11 patients with membranoproliferative glomerulonephritis. Lp(a) in MCD patients did not differ from that controls (101 +/- 102 and 90 +/- 115 mg/L) and correlated positively with total daily urinary protein loss (r = 0.7962, P less than 0.05). In contrast, the patients with membranoproliferative glomerulonephritis had significantly higher Lp(a) values than the controls (219 +/- 222 mg/L), and Lp(a) concentrations correlated negatively with the daily protein loss in urine (r = -0.6545, P less than 0.05). The most surprising results were the marked Lp(a) concentrations in serum of three patients with primary amyloidosis and nephrosis syndrome. Our results indicate a regulatory role of the kidney in the metabolism of Lp(a) and different effects on the serum Lp(a) concentration, depending on the type of damage to renal tissue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529062

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  Lipoprotein(a)

Authors:  J Scott
Journal:  BMJ       Date:  1991-09-21

2.  Lp(a) concentrations.

Authors: 
Journal:  BMJ       Date:  1991-11-02

Review 3.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

Review 4.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

5.  Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

Authors:  G Jerums; T J Allen; C Tsalamandris; A Akdeniz; A Sinha; R Gilbert; M E Cooper
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

6.  Fibrinogen, Lp(a), Microalbuminuria and Left Ventricular Mass Index: Cardiovascular Disease Risk factors in Diabetes.

Authors:  Satinder Kaur; Parminder Singh; Verma Indu; Gaurav Singla
Journal:  Indian J Clin Biochem       Date:  2011-12-25

7.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

8.  Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

Authors:  A J Jenkins; J S Steele; E D Janus; J D Santamaria; J D Best
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

9.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).

Authors:  H Dieplinger; C Lackner; F Kronenberg; C Sandholzer; K Lhotta; F Hoppichler; H Graf; P König
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus.

Authors:  A Császár; H Dieplinger; C Sandholzer; I Karádi; E Juhász; H Drexel; T Halmos; L Romics; J R Patsch; G Utermann
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.